The interaction of CD38 with BCR signaling may also be of clinical interest, as novel treatment strategies focusing on the inhibition of BCR pathway components like BTK and PI3 kinase δ have proven efficacy in CLL.[12,13]. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.